Amgen Inc. to Post FY2026 Earnings of $19.39 Per Share, SVB Leerink Forecasts (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGNGet Rating) – SVB Leerink issued their FY2026 earnings per share (EPS) estimates for shares of Amgen in a report issued on Sunday, May 22nd. SVB Leerink analyst G. Porges expects that the medical research company will post earnings of $19.39 per share for the year. SVB Leerink has a “Market Perform” rating and a $256.00 price target on the stock.

Several other research firms have also recently weighed in on AMGN. TheStreet cut Amgen from a “b+” rating to a “c+” rating in a research report on Wednesday, April 27th. Mizuho increased their target price on shares of Amgen from $202.00 to $208.00 in a report on Tuesday, May 10th. Oppenheimer cut shares of Amgen to an “outperform” rating and set a $285.00 price target on the stock. in a research report on Tuesday, May 3rd. Barclays increased their price objective on shares of Amgen from $233.00 to $236.00 and gave the stock an “equal weight” rating in a research note on Tuesday, April 12th. Finally, BMO Capital Markets lowered their target price on Amgen from $263.00 to $243.00 in a research report on Thursday, April 28th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $243.07.

Shares of NASDAQ AMGN opened at $249.04 on Tuesday. The company has a fifty day moving average price of $243.59 and a 200 day moving average price of $229.05. The firm has a market cap of $133.04 billion, a PE ratio of 24.51, a PEG ratio of 1.71 and a beta of 0.58. The company has a current ratio of 1.44, a quick ratio of 1.09 and a debt-to-equity ratio of 39.31. Amgen has a 1-year low of $198.64 and a 1-year high of $258.45.

Amgen (NASDAQ:AMGNGet Rating) last released its quarterly earnings data on Wednesday, April 27th. The medical research company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $4.22 by $0.03. The business had revenue of $6.24 billion for the quarter, compared to analysts’ expectations of $6.09 billion. Amgen had a return on equity of 165.95% and a net margin of 21.75%. During the same quarter in the previous year, the business posted $3.70 EPS.

Hedge funds have recently added to or reduced their stakes in the business. Dixon Hughes Goodman Wealth Advisors LLC bought a new stake in shares of Amgen during the fourth quarter worth $26,000. Rational Advisors LLC bought a new stake in Amgen during the first quarter valued at $26,000. Norwood Financial Corp acquired a new stake in Amgen during the fourth quarter worth approximately $28,000. Landmark Wealth Management LLC acquired a new stake in shares of Amgen during the 1st quarter worth approximately $28,000. Finally, Industrial Alliance Investment Management Inc. bought a new stake in Amgen in the fourth quarter valued at $31,000. 79.01% of the stock is currently owned by hedge funds and other institutional investors.

In other Amgen news, Director R Sanders Williams sold 600 shares of Amgen stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $250.00, for a total value of $150,000.00. Following the completion of the transaction, the director now directly owns 5,501 shares of the company’s stock, valued at approximately $1,375,250. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jonathan P. Graham sold 13,500 shares of the stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $241.81, for a total value of $3,264,435.00. Following the sale, the executive vice president now directly owns 37,333 shares in the company, valued at $9,027,492.73. The disclosure for this sale can be found here. 0.46% of the stock is currently owned by company insiders.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 8th. Stockholders of record on Tuesday, May 17th will be issued a dividend of $1.94 per share. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.12%. The ex-dividend date is Monday, May 16th. Amgen’s dividend payout ratio is presently 76.38%.

Amgen Company Profile (Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Featured Articles

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.